Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabogratinib in Low Grade Upper Tract Urothelial Carcinoma
NCT07265947Phase 2Recruiting
- Sponsor
- Tyra Biosciences
- Start
- Dec 2025
- Primary completion
- Oct 2030
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of dabogratinib in upper tract urothelial carcinoma (UTUC), sponsored by Tyra Biosciences. Started Dec 2025; status: recruiting.
02
Drugs
dabogratinib
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07265947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07265947.